ROCKVILLE, Md., Oct. 28, 2019 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE American: SYN), a diversified
clinical-stage company leveraging the microbiome to develop
therapeutics designed to prevent and treat gastrointestinal (GI)
diseases in areas of high unmet need, announced today that the
Company intends to release its operational highlights and financial
results for the quarter ended September 30,
2019 on Monday, November 4,
2019, and to host a conference call the same day at
4:30 p.m. ET. The dial-in information
for the call is as follows:
U.S. (toll free): 1-888-347-5280
International: +1 412-902-4280
Participants are asked to dial in 15 minutes before the
start of the call to register. The call will also be webcast over
the Internet
at https://www.webcaster4.com/Webcast/Page/1096/32094. An
archived replay of the call will be available for approximately
ninety (90) days at the same URL,
https://www.webcaster4.com/Webcast/Page/1096/32094 beginning
approximately one hour after the call's conclusion.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE American: SYN) is a diversified
clinical-stage company leveraging the microbiome to develop
therapeutics designed to prevent and treat gastrointestinal (GI)
diseases in areas of high unmet need. The Company's lead candidates
are: (1) SYN-004 (ribaxamase) which is designed to degrade certain
commonly used intravenous (IV) beta-lactam antibiotics within the
gastrointestinal (GI) tract to prevent microbiome damage, C.
difficile infection (CDI), overgrowth of pathogenic organisms,
the emergence of antimicrobial resistance (AMR) and acute
graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell
transplant (HCT) recipients, and (2) SYN-010, which is intended to
reduce the impact of methane-producing organisms in the gut
microbiome to treat an underlying cause of irritable bowel syndrome
with constipation (IBS-C). The Company is also advancing SYN-020,
an early-stage oral formulation of the enzyme intestinal alkaline
phosphatase (IAP) to treat both local GI and systemic diseases. For
more information, please visit Synthetic Biologics' website at
www.syntheticbiologics.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/synthetic-biologics-to-report-2019-third-quarter-operational-highlights-and-financial-results-on-november-4-2019-300946500.html
SOURCE Synthetic Biologics, Inc.